AZ cancer drug gets extended exclusivity

AstraZeneca got a bit of a windfall today from the FDA, which granted six extra months of exclusive marketing rights to its Arimidex cancer drug. The drug's patent was set to expire in December 2009.

Currently, Arimidex is approved as a first-line and add-on breast-cancer treatment. The drug brought in $507 million during the first nine months of this year. AZ had been studying Arimidex for use in children whose estrogen production is abnormally high, but the trial results weren't favorable enough for the company to seek a new indication.

- see the release from AstraZeneca

Related Articles:
Arimidex wins new indication. Report
Analyst: AZ "worst performer" in pharma

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.